Miglitol is an oral antihyperglycemic active pharmaceutical ingredient belonging to the alpha-glucosidase inhibitor class. It is a desoxynojirimycin derivative that works primarily within the gastrointestinal tract by reversibly inhibiting intestinal alpha-glucosidase enzymes involved in the digestion of carbohydrates. This delays carbohydrate breakdown and glucose absorption, helping reduce the rise in blood glucose that occurs after meals.
Miglitol is chemically identified as (2R,3R,4R,5S)-1-(2-hydroxyethyl)-2-(hydroxymethyl)piperidine-3,4,5-triol. It has the molecular formula C₈H₁₇NO₅, a molecular weight of 207.22 g/mol, and CAS Registry Number 72432-03-2. PubChem identifies Miglitol as an alpha-glucosidase inhibitor and a hypoglycemic agent.
As a pharmaceutical active ingredient, Miglitol API is relevant to the development and manufacture of oral formulations designed for glycemic control in adults with type 2 diabetes mellitus. Its mechanism differs from insulin secretagogues because Miglitol does not stimulate insulin secretion; instead, it acts locally in the intestinal tract to delay carbohydrate digestion.
Miglitol is described in official drug labeling as a white to pale-yellow powder that is soluble in water. The reported pKa is 5.9.
Miglitol is a synthetic carbohydrate-mimetic compound structurally related to 1-deoxynojirimycin. Its pharmacological activity is primarily associated with reversible inhibition of membrane-bound intestinal alpha-glucosidase enzymes.
These enzymes normally break down oligosaccharides and disaccharides into absorbable monosaccharides. By inhibiting this process, Miglitol slows carbohydrate digestion and glucose absorption, resulting in a smaller post-meal increase in blood glucose.
Miglitol is therefore an important API for pharmaceutical formulations addressing postprandial hyperglycemia and type 2 diabetes mellitus. Its distinct mechanism can provide an additional approach to glycemic management compared with therapies that increase insulin secretion.
The chemical and physical information above is supported by PubChem and official DailyMed labeling.
| Parameter | Specification |
|---|---|
| Appearance | White crystalline powder or crystals |
| Identification | IR & HPLC compliant |
| Assay (HPLC) | 98.0% – 102.0% |
| Loss on Drying | NMT 1.0% |
| Residue on Ignition | NMT 0.5% |
| Heavy Metals | NMT 10 ppm |
| Individual Impurity | NMT 0.5% |
| Total Impurities | NMT 1.0% |
| Water Content | NMT 1.0% |